Robert W. Dubois, MD, PhD, Describes the Initial Expectations of Accountable Care Organizations
Robert W. Dubois, MD, PhD, the chief science officer of the National Pharmaceutical Council discusses the initial expectations of implementing accountable care organizations (ACOs) and how those expectations have evolved over time.
This video was taken at the Academy of Managed Care Pharmacy's 25th Annual Meeting & Expo in San Diego, CA, on April 4, 2013.
Progress in treating multiple myeloma, or cancer of the plasma cells in bone marrow, has advanced significantly over the past decade. Today, questions about the disease often involve finding a treatment that balances the goal of putting a patient into remission – especially if stem cell transplantation is a possibility – against the toxicity of the treatment itself.
With grants from government sources looking less certain, partnerships between academic research center and pharmaceutical companies are more important than ever to keep breakthrough hematology therapies in the pipeline, said Burt Adelman, MD, a hematologist who serves as executive vice president and chief medical officer for Dyax Inc.
New therapies to treat chronic lymphocytic leukemia (CLL) will receive plenty of attention this week at the 55th American Society of Hematology Annual Meeting and Exposition in New Orleans. At an education session that opened the meeting Saturday, a physician with the Mayo Clinic made it clear that cost considerations are a reality for many older patients.